文献速递前列腺癌膀胱癌与上尿路尿路上皮癌前列腺增生与排尿功能障碍

评估泌尿外科实践中的财务毒性

Evaluating Financial Toxicity in Urologic Practice.
PubMed 文献 · Urology · 2023-06-22

这项横断面研究纳入182例在单中心接受肿瘤或良性泌尿外科手术的患者,使用COST量表及新型单条目测量在术前和术后评估财务毒性。结果显示四分之一患者存在中度至重度财务毒性,良性与肿瘤组间无统计学显著差异,单条目与COST强相关(r=-0.80)。

要点

  • 四分之一接受泌尿外科手术的患者存在中度至重度财务毒性。
  • 良性与肿瘤组财务毒性在术前和术后均无统计学显著差异。
  • 单条目财务毒性测量与COST量表强相关(r=-0.80)。

核心结论

  • COST调查和单条目财务毒性测量均是可用于评估泌尿外科财务毒性的有效工具。
  • 需要进一步研究以明确异质性泌尿外科患者群体中财务毒性的确切原因。

研究设计与样本

  • 单中心学术医疗中心的横断面研究,纳入182例接受肿瘤或良性泌尿外科手术的患者。
  • 肿瘤手术包括机器人辅助腹腔镜前列腺切除术、经尿道膀胱肿瘤电切术和根治性膀胱切除术。
  • 良性手术包括钬激光前列腺剜除术、膀胱内化学去神经术、输尿管镜激光碎石术和输尿管支架置换术。
  • 采用回顾性审查、患者访谈、经验证的COST调查及新型单条目测量在术前和术后进行评估。
  • 使用描述性统计和逻辑回归模型按泌尿外科手术类型比较COST评分。

主要发现

  • 80例(44%)患者接受肿瘤手术,102例(56%)接受良性手术。
  • 良性患者较肿瘤患者更可能收入较低且更年轻,中位年龄56.7岁 vs 64.9岁。
  • 四分之一接受泌尿外科手术的患者经历中度至重度财务毒性,良性与肿瘤组在术前或术后均无统计学显著差异。
  • 单条目测量在术前和术后均与COST强相关(r=-0.80)。

临床怎么用

  • 作者认为COST调查和单条目财务毒性测量均是可用于评估泌尿外科财务毒性的有效工具。
  • 作者指出需要进一步研究以明确异质性泌尿外科患者群体中财务毒性的确切原因。

局限性

  • 需要进一步研究以明确异质性泌尿外科患者群体中财务毒性的确切原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate financial toxicity in Urologic surgery using the Comprehensive Score for financial Toxicity (COST) as well as validate a single item measure of toxicity. METHODS: A cross-sectional study of 182 patients undergoing oncologic and benign urologic procedures at a single academic medical center. Oncologic procedures included robotic assisted laparoscopic prostatectomy, transurethral resection of bladder tumor, and radical cystectomy. Benign procedures included holmium laser enucleation of the prostate, intravesical chemodenervation, ureteroscopy laser lithotripsy, and ureteral stent exchange. Retrospective review, patient interviews, and the previously validated COST survey, as well as a novel single item measure of toxicity were used pre and post-op. Descriptive statistics and logistic regression models compared COST scores by type of urologic procedure. RESULTS: Eighty (44%) patients underwent oncologic procedures and 102 (56%) benign procedures. Benign patients were most likely to have lower income and be younger than oncologic patients, with a median age of 56.7 vs 64.9. One in 4 patients undergoing urologic procedures experienced moderate to severe financial toxicity, without a statistically significant difference between the benign and the oncology groups pre- or post-operatively. Single item measure strongly correlated with COST (r = -0.80) pre- and post-operative. CONCLUSION: The COST survey and a single-item financial toxicity measure are both valid tools that can be used to measure financial toxicity in urology. Further research is needed to elicit the exact cause of financial toxicity in the heterogenous urologic patient population.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Glazyrine V, Au D, Starkey J, et al. Evaluating Financial Toxicity in Urologic Practice. Urology. 2023. PMID: 37353088. doi:10.1016/j.urology.2023.04.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。